Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 25, 2026 11:05 ET | Source: Hagens Berman Sobol Shapiro LLP

ImmunityBio (IBRX) Facing Lawsuit After FDA Flags Misleading Cancer Claims, Shares Plunge 21%, $2B Market Cap Lost -- HBSS

Investors who lost money in IBRX after its stock plunged due to allegedly misleading financial statements are urged to contact Hagens Berman.
May 22, 2026 12:48 ET | Source: Hagens Berman Sobol Shapiro LLP

IBRX 4-DAY DEADLINE ALERT: ImmunityBio (IBRX) Investors Face Losses Amid FDA Warning Regarding Unsupported Cancer Treatment Claims – Hagens Berman

Investors who lost money in IBRX after its stock plunged due to allegedly misleading financial statements are urged to contact Hagens Berman.
May 19, 2026 09:14 ET | Source: Berger Montague

CLASS ACTION REMINDER: Berger Montague Advises ImmunityBio, Inc. (NASDAQ: IBRX) Investors to Inquire About a Securities Fraud Lawsuit by May 26, 2026

PHILADELPHIA, May 19, 2026 (GLOBE NEWSWIRE) -- National plaintiffs’ law firm Berger Montague PC announces a class action lawsuit against ImmunityBio, Inc. (NASDAQ: IBRX) (“ImmunityBio” or the...
May 19, 2026 09:06 ET | Source: Hagens Berman Sobol Shapiro LLP

ImmunityBio (IBRX) Facing Lawsuit After FDA Flags Misleading Cancer Claims, Shares Plunge 21%, $2B Market Cap Lost -- Hagens Berman

Investors who lost money in IBRX after its stock plunged due to allegedly misleading financial statements are urged to contact Hagens Berman.
May 15, 2026 11:10 ET | Source: Hagens Berman Sobol Shapiro LLP

IBRX INVESTOR NOTICE: ImmunityBio (IBRX) Facing Lawsuit After FDA Flags Misleading Cancer Claims, Shares Plunge 21%, $2B Market Cap Lost -- Hagens Berman

Investors who lost money in IBRX after its stock plunged due to allegedly misleading financial statements are urged to contact Hagens Berman.
May 12, 2026 16:26 ET | Source: Hagens Berman Sobol Shapiro LLP

IBRX 2-WEEK DEADLINE ALERT: ImmunityBio (IBRX) Investors Face Losses Amid FDA Warning Regarding Unsupported Cancer Treatment Claims -- Hagens Berman

Investors who lost money in IBRX after its stock plunged due to allegedly misleading financial statements are urged to contact Hagens Berman.
May 06, 2026 17:26 ET | Source: Hagens Berman Sobol Shapiro LLP

IBRX Lawsuit Alleges Company Allegedly Violated Drug Promotion Laws - ImmunityBio Investors Face Losses Following Company Allegedly Violated Drug Promotion Laws: Hagens Berman

Investors who lost money in IBRX after its stock plunged due to allegedly misleading financial statements are urged to contact Hagens Berman.
May 04, 2026 10:56 ET | Source: Hagens Berman Sobol Shapiro LLP

IBRX Lawsuit Alleges Company Allegedly Violated Drug Promotion Laws - ImmunityBio Investors Face Losses Following Company Allegedly Violated Drug Promotion Laws: Hagens Berman

Investors who lost money in IBRX after its stock plunged due to allegedly misleading financial statements are urged to contact Hagens Berman.
May 01, 2026 12:00 ET | Source: Hagens Berman Sobol Shapiro LLP

IBRX SHAREHOLDER UPDATE: ImmunityBio (IBRX) Sued After FDA Flags Misleading Cancer Claims, Shares Plunge 21%, $2B Market Cap Lost -- Hagens Berman

Investors who lost money in IBRX after its stock plunged due to allegedly misleading financial statements are urged to contact Hagens Berman.
April 28, 2026 19:31 ET | Source: Hagens Berman Sobol Shapiro LLP

INVESTOR DEADLINE: ImmunityBio, Inc. (IBRX) Investors with Substantial Losses Have Opportunity to Lead the ImmunityBio Class Action Lawsuit– Hagens Berman

Investors who lost money in IBRX after its stock plunged due to allegedly misleading financial statements are urged to contact Hagens Berman.